scholarly article | Q13442814 |
P356 | DOI | 10.1046/J.1365-2516.1997.00073.X |
P698 | PubMed publication ID | 27214623 |
P2093 | author name string | United Kingdom Haemophilia Centre Directors Organisation Executive Committee | |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | hemophilia | Q134003 |
hemophilia A | Q2092064 | ||
P304 | page(s) | 63-77 | |
P577 | publication date | 1997-01-01 | |
P1433 | published in | Haemophilia | Q15753375 |
P1476 | title | GUIDELINES ON THERAPEUTIC PRODUCTS TO TREAT HAEMOPHILIA AND OTHER HEREDITARY COAGULATION DISORDERS. | |
P478 | volume | 3 |
Q33785738 | Audit of clinical management of von Willebrand disease during 1997 at a single institution and review of treatment patterns between 1980 and 1997. |
Q41578620 | Batch recall of French plasma-derived products due to variant Creutzfeldt-Jakob disease risk: the psychological impact on haemophilic patients, changes in their therapeutic demands and behaviour and ethical considerations. |
Q24684165 | C1 inhibitor deficiency: consensus document |
Q36381542 | Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience |
Q37619008 | Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran |
Q45888910 | Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia |
Q38024851 | Dealing with the uncertain risk of variant Creutzfeldt-Jakob disease transmission by coagulation replacement products |
Q45270351 | Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash |
Q45885096 | Experience of prophylaxis treatment in children with severe haemophilia |
Q38165089 | Guidance on the dental management of patients with haemophilia and congenital bleeding disorders |
Q33815761 | Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy |
Q34229310 | Haemophilias: advances towards genetic engineering replacement therapy |
Q45889715 | Hepatitis in haemophilia |
Q43622975 | Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America |
Q45888311 | Neoantigens and antibodies to factor VIII. |
Q45888117 | New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee UK Haemophilia Directors' Organisation |
Q45877518 | Potency estimation of recombinant factor VIII: effect of assay method and standard |
Q38109706 | Purchasing factor concentrates in the 21st century through competitive tendering |
Q41711748 | Recombinant coagulation factors |
Q34202036 | Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease |
Q39871501 | Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders |
Q45873337 | Spontaneous intracranial bleeding in two patients with congenital afibrinogenaemia and the role of replacement therapy |
Q34574267 | State of care for hemophilia in pediatric patients |
Q45872630 | The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). |
Q45888459 | The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison |
Q37702839 | The evaluation of fibrin sealants and tissue adhesives in oral surgery among patients with bleeding disorders |
Q45873704 | The responsibility of separating truth from myth to patient and family |
Q45873317 | Unexpected presentation of type 2N von Willebrand disease in pregnancy |
Q33992794 | Viral inactivation of fresh frozen plasma |
Q47918948 | von Willebrand disease and its management in oral and maxillofacial surgery |
Search more.